Atara Biotherapeutics (NASDAQ:ATRA) Announces Quarterly Earnings Results

Atara Biotherapeutics (NASDAQ:ATRA) released its quarterly earnings results on Tuesday. The biotechnology company reported ($2.93) EPS for the quarter, beating analysts’ consensus estimates of ($3.77) by $0.84, Zacks reports. The company had revenue of $40.19 million during the quarter, compared to the consensus estimate of $23.00 million. During the same quarter last year, the firm posted ($16.50) EPS.

Atara Biotherapeutics Stock Performance

Shares of ATRA stock traded down $0.30 during trading hours on Thursday, hitting $13.96. 43,751 shares of the company were exchanged, compared to its average volume of 106,571. Atara Biotherapeutics has a fifty-two week low of $6.50 and a fifty-two week high of $39.50. The company has a 50 day simple moving average of $8.89 and a two-hundred day simple moving average of $10.30. The firm has a market cap of $68.54 million, a P/E ratio of -0.55 and a beta of 0.50.

Wall Street Analyst Weigh In

A number of analysts have weighed in on ATRA shares. HC Wainwright reissued a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st. Canaccord Genuity Group increased their price objective on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday. The Goldman Sachs Group lowered their target price on shares of Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating for the company in a research note on Wednesday, July 17th. Finally, Mizuho upgraded Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and decreased their price target for the stock from $25.00 to $18.00 in a report on Friday, August 16th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $16.67.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.